AU2003301245A1 - Clofarabine and camptothecin chemotherapy combination - Google Patents

Clofarabine and camptothecin chemotherapy combination

Info

Publication number
AU2003301245A1
AU2003301245A1 AU2003301245A AU2003301245A AU2003301245A1 AU 2003301245 A1 AU2003301245 A1 AU 2003301245A1 AU 2003301245 A AU2003301245 A AU 2003301245A AU 2003301245 A AU2003301245 A AU 2003301245A AU 2003301245 A1 AU2003301245 A1 AU 2003301245A1
Authority
AU
Australia
Prior art keywords
clofarabine
camptothecin
chemotherapy combination
chemotherapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003301245A
Other versions
AU2003301245A8 (en
Inventor
Katherine Stephenson
Steven D. Weitman
Sean T. Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ilex Products Inc
Original Assignee
Ilex Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilex Products Inc filed Critical Ilex Products Inc
Publication of AU2003301245A1 publication Critical patent/AU2003301245A1/en
Publication of AU2003301245A8 publication Critical patent/AU2003301245A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003301245A 2002-10-16 2003-10-14 Clofarabine and camptothecin chemotherapy combination Abandoned AU2003301245A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41906502P 2002-10-16 2002-10-16
US60/419.065 2002-10-16
US45947603P 2003-04-01 2003-04-01
US60/459.476 2003-04-01
PCT/US2003/032515 WO2004035033A2 (en) 2002-10-16 2003-10-14 Clofarabine and camptothecin chemotherapy combination

Publications (2)

Publication Number Publication Date
AU2003301245A1 true AU2003301245A1 (en) 2004-05-04
AU2003301245A8 AU2003301245A8 (en) 2004-05-04

Family

ID=32110211

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003301245A Abandoned AU2003301245A1 (en) 2002-10-16 2003-10-14 Clofarabine and camptothecin chemotherapy combination

Country Status (2)

Country Link
AU (1) AU2003301245A1 (en)
WO (1) WO2004035033A2 (en)

Also Published As

Publication number Publication date
WO2004035033A2 (en) 2004-04-29
WO2004035033A3 (en) 2004-07-22
AU2003301245A8 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
AU2003282478A1 (en) Discount-instrument methods and systems
EP1573463A3 (en) Alternate delivery location methods and systems
AU2003286819A1 (en) Alternate delivery location methods and systems
EP1545481A4 (en) Combination chemotherapy compositions and methods
AU2003252586A1 (en) Individual cryptoprotective complex
AU2003258714A1 (en) Immune modulatory compounds and methods
AU2003266321A1 (en) Tetrahydropyrimidine-2-one derivatives and their uses
AU2003241340A1 (en) Preparing and presenting content
AU2003297037A1 (en) Illuminant and method
AU2003220653A1 (en) Interconnection structure and methods
AU2002364051A1 (en) Anti-cancer combination and use thereof
AU2003220350A1 (en) Full bore selective location and orientation system
AU2003285656A1 (en) System with macrocommands
AU2003296369A1 (en) Imminoamines and preparation thereof
AU2003232077A1 (en) Cyclic peptide anti-cancer agents and methods
GB0207362D0 (en) Chemotherapy
GB0208516D0 (en) Chemotherapy
AU2003210541A1 (en) Health improvement systems and methods
AU2003214038A1 (en) Peptides with anti-hypertensive properties
AUPS198302A0 (en) Improvements in bowsprits
AU2003231827A1 (en) Pseudo-tissues and uses thereof
AU2003302173A1 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003301245A1 (en) Clofarabine and camptothecin chemotherapy combination
AU2003277416A1 (en) Clofarabine and platinum chemotherapy combination
AU2003287081A1 (en) Clofarabine and taxane chemotherapy combination

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase